Becky Pferdehirt | Partner
Andreessen Horowitz

Day 3 - November 30 @ 09:40

Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

• Could new platform technologies enable us to develop countermeasures rapidly enough to stop emerging viral threats before pandemics ensue?
• Are broad-spectrum (pan-variant) prophylactics a possible way forward?
• When will we see the first clinically approved mRNA or DNA-encoded therapeutics, from gene-editing to immunotherapy?
• Could advances in AI and synthetic biology enable personalized medicines (e.g. for cancers) to be developed at a population scale?
• Would regulators agree to accelerate approval of platform-based medicines based on the safety and efficacy of different candidates from the same platform?
• Can Government, biopharma, and venture capital co-fund platform technologies, especially for technologies of dual commercial and national security interest?

Moderator: Riley Griffin, Health Reporter, Bloomberg

×

Riley Griffin / Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

Riley Griffin, Health Reporter,
Bloomberg

Riley Griffin is a journalist for Bloomberg News, where she reports on health policy, biosecurity and pandemic preparedness. Based in Washington, D.C., Riley covers how the US is working to counter naturally occurring, accidental and deliberate health threats. She received a Front Page Award for...

CloseMore

Ariel Weinberger, Chief Executive Officer, Autonomous Therapeutics

×

Ariel Weinberger / Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

Ariel Weinberger, Chief Executive Officer,
Autonomous Therapeutics

Dr. Ariel Weinberger is the CEO & Founder of Autonomous Therapeutics. Ari started Autonomous from a single bench in the Brooklyn Navy Yard in 2017, and grew the company to a team of more than 20 at Johnson & Johnson’s JLABS incubator in New York City. At JLABS, Autonomous was selected as...

CloseMore

Vic Suarez, COL (Ret), US Army; Founder & Senior Partner, BluZoneBio

×

Vic Suarez / Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

Vic Suarez, COL (Ret), US Army; Founder & Senior Partner,
BluZoneBio

Vic Suarez, Colonel (Ret), US Army, MS, PMP, CMRP is the Founder and Principal Growth Partner of Blu Zone Bioscience & Supply Chain Solutions, LLC. Blu Zone Bio assists biotechnology and life science supply chain organizations accelerate growth and expand domestic biomanufacturing through...

CloseMore

Hamilton Bennett, Sr. Director Vaccine Access and Partnerships, Moderna

×

Hamilton Bennett / Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

Hamilton Bennett, Sr. Director Vaccine Access and Partnerships,
Moderna

Hamilton Bennett (she/her) is the Senior Director of Vaccine Access and Partnerships at Moderna, a company pioneering messenger RNA (mRNA) therapeutics and vaccines. Hamilton maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed...

CloseMore

Becky Pferdehirt, Partner, Andreessen Horowitz

×

Becky Pferdehirt / Keynote Panel: Platforms of the future: from precision therapies to synthetic immune systems

Becky Pferdehirt, Partner,
Andreessen Horowitz

Becky Pferdehirt is an investing partner on the a16z Bio + Health team. Prior to joining Andreessen Horowitz, Becky worked at Amgen where she most recently led business development efforts for therapeutic platform partnerships. Before moving to BD Becky was a research scientist in Amgen...

CloseMore